Why is making insulin through recombinant DNA better than extracting it from animals?

Producing insulin through recombinant DNA technology allows for a more standardized and scalable production process, ensuring consistent quality and supply. It eliminates the need for animal extraction, reducing ethical concerns and the risk of impurities or allergic reactions associated with animal-derived insulin. Additionally, recombinant insulin can be modified to better suit individual patient needs.